A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally ... compared to other antidiabetic drugs. 4 These observations were based on 100 million patient records ...

At least nine patients using the glucagon-like peptide 1 (GLP-1 ... patients (mean age, 57.4 years; 56% women) who developed ophthalmic complications while using semaglutide (n = 6) or tirzepatide ...

12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

Past studies have found a potential link between semaglutide and the eye condition ... it’s important for researchers to continue to examine how GLP-1 medications might impact other areas ...